蘋果:iPhone 12符合輻射規定 質疑法國調查結果
法國宣布,由於電磁波輻射值(SAR)超標,蘋果(AAPL.US)必須停止在法國銷售iPhone 12。德國網絡監管機構 BNetzA表示可能會啟動類似程序,並與法國當局保持密切聯繫,而西班牙OCU消費者組織亦敦促當局停止銷售iPhone 12。
不過蘋果發聲明稱,iPhone 12已獲得多個國際機構的認證,符合全球輻射標準,根據蘋果內部及第三方實驗室提供的結果,可證明手機符合法國機構的要求,質疑法國調查的準確性。
法國數碼經濟部部長Jean-Noel Barrot表示,蘋果在軟件更新後將可解決輻射問題,預計蘋果將在兩周內作出回應,否則會下令回收所有在市面流通的iPhone 12。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.